Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Polycythemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    92 result(s) found for: Polycythemia. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2021-004732-29 Sponsor Protocol Number: PTG-300-11 Start Date*: 2022-06-01
    Sponsor Name:Protagonist Therapeutics, Inc.
    Full Title: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036057 Polycythaemia vera PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) CZ (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) IT (Ongoing) NL (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004717-25 Sponsor Protocol Number: Low-PV Start Date*: 2016-07-08
    Sponsor Name:FONDAZIONE PER LA RICERCA OSPEDALE MAGGIORE DI BERGAMO - FROM
    Full Title: The benefit/risk profile of pegylated proline-Interferon alpha-2b (AOP2014) added to the best available strategy based on phlebotomies in low-risk patients with Polycythemia Vera (PV). The Low-PV r...
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018768-18 Sponsor Protocol Number: P11012010 Start Date*: 2010-07-02
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: An open-label, prospective, multicentre, phase I/II dose escalation study to determine the maximum tolerated dose and to assess the safety and efficacy of P1101, PEG-Proline-Interferon alpha-2b for...
    Medical condition: Diagnosis for Polycythemia Vera as per the WHO or PVSG.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007801-63 Sponsor Protocol Number: 1113/08 Start Date*: 2010-01-07
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: International Study using Clopidogrel and Aspirin for the treatment of Polycythemia Vera.
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036057 Polycythaemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001908-11 Sponsor Protocol Number: RG_16-148 Start Date*: Information not available in EudraCT
    Sponsor Name:UNIVERSITY OF BIRMINGHAM
    Full Title: A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha as first line ThErapyfor high risk polycythemia vera
    Medical condition: Myeloproliferative neoplasm (MPN), specifically Polycythaemia Vera
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001356-31 Sponsor Protocol Number: PEN-PV Start Date*: 2015-05-20
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: An open-label, single arm, Phase III study to assess the self-administration of AOP2014 using a pre-filled pen, developed for the treatment of Polycythemia Vera patients
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) AT (Completed) CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-003704-40 Sponsor Protocol Number: ISIS702843-CS4 Start Date*: 2023-02-27
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Pol...
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001309-42 Sponsor Protocol Number: CINC424B2001X Start Date*: 2014-10-23
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, Expanded Treatment Protocol (ETP) of ruxolitinib in patients with Polycythemia Vera who are Hydroxyurea resistant or intolerant and for whom no treatment alternatives a...
    Medical condition: hydroxyurea resistant or intolerant patients with polycythemia vera
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NO (Completed) SK (Completed) PT (Completed) SE (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-007335-99 Sponsor Protocol Number: Tarceva-HH-2008 Start Date*: 2009-08-24
    Sponsor Name:Herlev Hospital, Dept. of Haematology (L121)
    Full Title: A Phase II Study of Erlotinib in Patients with Polycythaemia Vera and Essential Thrombocythemia
    Medical condition: Polycythaemia Vera & Essential Thrombocythaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015494 Essential thrombocythemia LLT
    9.1 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020807-57 Sponsor Protocol Number: CINC424B2301 Start Date*: 2011-02-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Randomized, open label, multicenter phase III study of Efficacy and Safety in Polycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst ...
    Medical condition: Polycythemia vera
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GB (Completed) IT (Completed) NL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-012784-34 Sponsor Protocol Number: 384/09 Start Date*: 2009-07-08
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: STUDY OF HYDROXYUREA MECHANISMS OF ACTION ON LEUKOCYTE ACTIVATION IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE SYNDROMES.
    Medical condition: MYELOPROLIFERATIVE SYNDROMES
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015493 LLT
    9.1 10036057 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006647-45 Sponsor Protocol Number: D1060C00001 Start Date*: 2009-05-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 inhibitor AZD1480 Administered Orally to Patients with Primary ...
    Medical condition: Myeloproliferative disorders including Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028578 Myeloproliferative disorders (excl leukaemias) HLT
    9.1 10036057 Polycythaemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003583-31 Sponsor Protocol Number: CINC424B2401 Start Date*: 2014-02-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Randomized, open label, multicenter phase IIIb study evaluating the efficacy and safety of ruxolitinib versus best available therapy in patients with polycythemia vera who are hydroxyurea resistant...
    Medical condition: Polycythemia vera resistant or intolerant to hydroxyurea
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) HU (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000860-27 Sponsor Protocol Number: DSC/12/2357/45 Start Date*: 2013-06-20
    Sponsor Name:ITALFARMACO S.p.A
    Full Title: A two-part study to assess the safety and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera
    Medical condition: JAK2V617F positive Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) DE (Completed) GB (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-019500-23 Sponsor Protocol Number: MPD-RC111 Start Date*: 2012-02-15
    Sponsor Name:CONSORZIO MARIO NEGRI SUD
    Full Title: Single Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High Risk Polycythemia Vera or High Risk Essential Thrombocythemia who are Either Hydroxyurea Resistant or Intolerant ...
    Medical condition: High risk polycythemia vera and high risk essential thrombocythemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036057 Polycythaemia vera PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005259-18 Sponsor Protocol Number: PROUD-PV Start Date*: 2013-08-15
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) IT (Completed) SK (Completed) AT (Completed) BG (Completed) DE (Completed) PL (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001382-28 Sponsor Protocol Number: INCB 18424-256 Start Date*: 2008-09-19
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, open label, dose regimen ranging clinical study to determine the safety and efficacy of INCB018424 in patients with advanced polycythemia vera or essential thrombocythemia refractory ...
    Medical condition: advanced polycythemia vera or essential thrombocythemia refractory to hydroxyurea
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036057 Polycythaemia vera LLT
    9.1 10015494 Essential thrombocythemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004105-11 Sponsor Protocol Number: GS-US-354-0101 Start Date*: 2014-07-04
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 2, Open-label, Randomized Study to Evaluate Safety and Efficacy of Momelotinib in Subjects with Polycythemia Vera or Essential Thrombocythemia
    Medical condition: subjects with either polycythemia vera (PV) or essential thrombocythemia (ET)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036057 Polycythaemia vera PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003295-12 Sponsor Protocol Number: 15022013 Start Date*: 2013-10-31
    Sponsor Name:Roskilde University Hospital
    Full Title: Combination Therapy Interferon Alpha + JAK1-2 Inhibitor in The Ph-Negative Chronic Myeloid Neoplasms
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10028538 Myelofibrosis with myelometaplasia LLT
    18.1 100000004864 10036061 Polycythemia vera LLT
    18.1 100000004864 10053134 Osteomyelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005306-49 Sponsor Protocol Number: MK-0683-092 Start Date*: 2008-09-03
    Sponsor Name:Department of Haematology, Herlev Hospital, University of Copenhagen
    Full Title: A Phase II Study of Vorinostat in Patients with Polycythaemia Vera and Essential Thrombocythaemia
    Medical condition: patients with polycythaemia vera or essential thrombocythaemia or myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036057 Polycythaemia vera LLT
    9.1 10015493 Essential thrombocythaemia LLT
    12.1 10028537 Myelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 16:21:48 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA